InsidersTradesSigma
Follow the 新和成 stock price and the full directors' dealings record of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 新和成 has logged 1 reports. Market capitalisation: €93.8bn. The latest transaction was disclosed on 15 July 2021 (Purchase). Among the most active insiders: 胡柏藩. All data is free.
1
Insider Decl.
n/a
Thresholds
€3,673
1 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,651 of 29,056 companies
74.7
score / 100
Value71
Quality78
FCF yld7.4%
Earn yld7.2%
EV/EBITDA9.8x
ROE20%
Gross mgn45%
Net mgn30%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 July 2021
About 新和成
新和成 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of pharmaceutical products.